Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01445028 · ClinicalTrials.gov registry record · Phase 4
Isotretinoin for Proliferative Vitreoretinopathy
A Phase 4 study, sponsored by Wills Eye.
- Completed
- Registry status
- Phase 4
- Development phase
- 109
- Enrollment target
NCT01445028 is a Phase 4 study that has completed, run by Wills Eye. The registered enrollment target is 109 participants.
The verdict
NCT01445028, a Phase 4 study, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 109 participants
- Enrollment target
Study Summary
Proliferative vitreoretinopathy (PVR), or secondary scarring on and around the retina, is an important cause of retinal re-detachment. The purpose of this study is to evaluate the effect of oral isotretinoin, which inhibits the growth of cells responsible for proliferative vitreoretinopathy (PVR), on recurrent retinal detachment.
Interventions
- DRUG Isotretinoin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2011-09 |
| Est. Completion | 2015-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01445028
The ClinicalTrials.gov registry entry for NCT01445028 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wills Eye, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Isotretinoin is the first listed.
NCT01445028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01445028 about?
NCT01445028 is a clinical study titled "Isotretinoin for Proliferative Vitreoretinopathy". Proliferative vitreoretinopathy (PVR), or secondary scarring on and around the retina, is an important cause of retinal re-detachment. The purpose of this study is to evaluate the effect of oral isotretinoin, which inhibits the growth of cells responsible for proliferative vitreoretinopathy (PVR), o...
What is the current status of trial NCT01445028?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 109 participants. The study started on 2011-09. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01445028?
The interventions under investigation include: Isotretinoin (DRUG).
Who is sponsoring clinical trial NCT01445028?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.